Loading organizations...
Aravis SA is a private equity firm specializing in high-tech growth investments, primarily in Switzerland. The firm acts as a hands-on investor, providing strategic guidance and capital to scale technology companies. Its "Aravis Growth" initiative builds a portfolio across Biotech, Creative and Digital, and Industrial High Tech, advancing businesses towards international success.
Jean-Philippe Tripet founded Aravis SA in 2001, leveraging an extensive finance career. Prior to the firm's establishment, Tripet gained significant private equity experience since 1994, holding senior roles at UBS and Lombard Odier & Cie. This background, including supervision of numerous private investments, underpins the firm’s deeply engaged philosophy.
Aravis partners with visionary entrepreneurs and teams focused on technological advancement. Beyond capital, the firm offers strategic advice and domain expertise to accelerate growth. Its mission involves supporting and guiding entrepreneurs to pursue their visions, nurturing innovative businesses to achieve market prominence and full potential.
Key people at Aravis.
Aravis was founded in 2001 by Jean-Philippe Tripet (Founder and Chairman).
Aravis was founded in 2001 by Jean-Philippe Tripet (Founder and Chairman).
Aravis has 5 tracked investments across 4 companies. The latest tracked deal is $15.0M Series B in Bird Rock Bio in March 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2014 | Bird Rock Bio | $15.0M Series B | — | 5AM Ventures, Bain Capital Life Sciences, INKEF Capital, Longwood Fund, OrbiMed, SR ONE, The Column Group, Apposite Capital, GlaxoSmithKline, M Ventures, Versant Ventures |
| Oct 1, 2010 | Synosia Therapeutics | $30.0M Series C | Greg Duncan | RED Tree Venture Capital, 5AM Ventures, Investor Growth Capital, Novo Holdings, Swiss Helvetia Fund, Versant Ventures |
| Dec 15, 2009 | Evolva | $15.3M Series B Extension | — | Auriga Partners, Vinci Capital/renaissance PME, Wellington Partners |
| Sep 11, 2009 | Evolva | $24.1M Other Equity | — | Dansk Innovationsinvestering, DRX Capital, Sunstone Capital |
| Jul 1, 2006 | Ambrx | $52.0M Series C | Apposite Capital | Maverick Capital, 5AM Ventures, CMEA Capital, DOW Employees Pension Plan, Glynn Capital, Roche, Tavistock Group, Versant Ventures |
Key people at Aravis.
